Welcome to our dedicated page for Novelstem Intl SEC filings (Ticker: NSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovelStem International Corp. (NSTM) SEC filings page on Stock Titan is designed to help readers understand the company’s regulatory disclosures and how they relate to its merger-focused strategy. As a publicly traded SEC-reporting company, NovelStem uses its filings to describe material developments such as strategic repositioning, debt reduction transactions and the status of its historical investment in NewStem Ltd.
In its annual report disclosures, NovelStem has discussed the liquidation of NewStem, the reversion of the associated stem-cell-based technology and license to Yissum, and the company’s remaining contractual rights to share in potential future monetization of that intellectual property. Filings also provide detail on NovelStem’s notes payable, convertible debt and other liabilities, as well as the steps it has taken to extinguish litigation funding debt through the sale of its interest in the Netco Partners joint venture.
On this page, users can review key SEC documents such as annual reports on Form 10-K and other periodic or current reports that explain NovelStem’s financial position, contingent rights related to the NewStem technology, and its stated focus on seeking a merger partner. Stock Titan enhances these filings with AI-powered summaries that highlight important sections, clarify technical language and point out items that may be relevant to shareholders, such as balance sheet changes or material strategic updates.
Readers interested in NovelStem’s merger platform strategy, its debt restructuring efforts, or the potential impact of any monetization of the NewStem intellectual property can use this page to quickly navigate the company’s SEC reporting history and better understand the context behind its public announcements.
NovelStem International Corp. filed its Q3 2025 report, showing a swing to profitability driven by non-operating items and significant liability reduction. For the nine months ended September 30, 2025, the company reported net income of $2,469,177 versus a loss a year ago, primarily from relief of indebtedness income of $1,697,024 and a $1,171,760 gain on disposal of its 50% interest in NetCo, which was used to settle a litigation funding liability.
Operating activity remains minimal: administrative fee income was zero and G&A fell to $198,007 from $893,887. Liquidity is tight with cash of $627 and current liabilities of $2,067,209 at September 30, 2025, though these liabilities declined from $5,304,486 after the NetCo transaction. The company disclosed substantial doubt about its ability to continue as a going concern and is pursuing fundraising and potential monetization of former NewStem licenses (up to $3,750,000). It also reported material weaknesses in internal control. Common shares outstanding were 46,881,475 as of November 12, 2025.